VISTA Emerges as a Promising Immunotherapy Target in Cancer – Targeted Oncology

Read article - Features comments by Randolph J. Noelle, a professor of microbiology and immunology, in a review about the role of VISTA (V-domain immunoglobulin suppressor of T-cell activation) as a promising target in cancer immunotherapy. “VISTA is an exciting new target on its own and in combination with other checkpoint inhibitors,” Noelle said. “VISTA can control the steady-state activity of the resting immune system and should allow for heightened antitumor immune response.”